Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Balaña, C.
Right arrow Articles by Rosell, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balaña, C.
Right arrow Articles by Rosell, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1425-1429, 2003
© 2003 European Society for Medical Oncology

Original Paper

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site

C. Balaña1,+, J.-L. Manzano1, I. Moreno3, B. Cirauqui1, A. Abad1, A. Font1, J.-L. Mate2 and R. Rosell1

1 Medical Oncology Service, 2 Pathology Service, Hospital Germans Trias i Pujol, Barcelona; 3 Hospital Municipal de Badalona, Barcelona, Spain

Received 12 February 2003; revised 28 March 2003; accepted 14 April 2003

Background:

The aim of this phase II study was to determine toxicity, response rate, time to progression, and overall survival of cisplatin, etoposide and gemcitabine in patients with carcinoma of unknown primary tumour site.

Patients and methods:

Thirty patients with no previous chemotherapy and not belonging to a treatable group were treated with cisplatin 70 mg/m2 on day 1, etoposide 70 mg/m2 on days 1 and 2, and gemcitabine 700 mg m2 on days 1 and 8, administered every 3 weeks. Stable or responding patients received a maximum of eight cycles. Twenty patients (67%) had more than three affected sites, and 25 patients (84%) had adenocarcinomas.

Results:

Overall response rate was 36.6% (11 patients), including four complete responses (13.3%) and seven partial responses (23.3%), with a 95% confidence interval of 19.9–56. Median survival was 7.21 months and eight patients remained alive for >1 year. Myelosuppression was the most important toxicity, with grade 3–4 neutropenia in 18 patients (60%) in 32% of the cycles: eight patients had neutropenic fever and 10 patients had thrombopenia in 11% of cycles. No non-haematological grade 4 toxicity occurred.

Conclusions:

Cisplatin, etoposide and gemcitabine is an active combination, inducing objective responses in a subset of heavily advanced disease patients with carcinoma of unknown primary site. The role of adding gemcitabine to cisplatin and etoposide remains to be resolved as to the best schedule to diminish toxicity for the three-drug combination.

Key words: chemotherapy, gemcitabine, unknown primary site


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
Y. H. Park, B.-Y. Ryoo, S.-J. Choi, S. H. Yang, and H.-T. Kim
A Phase II Study of Paclitaxel plus Cisplatin Chemotherapy in an Unfavourable Group of Patients with Cancer of Unknown Primary Site
Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 681 - 685.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.